Experienced in Gliosarcoma

Dr. Sukeshi P. Arora

Oncology | Hematology | Hematology Oncology
The University Of Texas Health Science Center At San Antonio
7703 Floyd Curl Dr, Suite Mc7977, 
San Antonio, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Gliosarcoma
The University Of Texas Health Science Center At San Antonio
7703 Floyd Curl Dr, Suite Mc7977, 
San Antonio, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sukeshi Arora is an Oncologist and a Hematologist in San Antonio, Texas. Dr. Arora is rated as an Experienced provider by MediFind in the treatment of Gliosarcoma. Her top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), and Familial Pancreatic Cancer. Dr. Arora is currently accepting new patients.

Her clinical research consists of co-authoring 32 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Hematology Oncology
Licenses
Internal Medicine in TX
Hospital Affiliations
University Health System
Languages Spoken
English
Hindi
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community First Health Plans
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO
7703 Floyd Curl Dr, Suite Mc7977, San Antonio, TX 78229

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Oxaliplatin, Irinotecan Hydrochloride, Leucovorin Calcium, Fluorouracil
Study Phase: Phase 3
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC)
A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC)
Enrollment Status: Completed
Publish Date: May 01, 2024
Intervention Type: Other, Dietary supplement
Study Phase: Phase 2
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 19, 2022
Intervention Type: Drug, Procedure
Study Drugs: Fluorouracil, Gemcitabine hydrochloride, Irinotecan hydrochloride, Oxaliplatin, Paclitaxel albumin-stabilized nanoparticle formulation
Study Phase: Phase 2
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: June 28, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Nab-paclitaxel, Gemcitabine
Study Phase: Phase 1/Phase 2
Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy
Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy
Enrollment Status: Terminated
Publish Date: April 12, 2022
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 6 Less Clinical Trials

32 Total Publications

Real-World Experiences Using Atezolizumab + Bevacizumab for the Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Study.
Real-World Experiences Using Atezolizumab + Bevacizumab for the Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Study.
Journal: Cancers
Published: April 18, 2025
Similar Doctors
Advanced in Gliosarcoma
Dr. Selena J. Stuart
Hematology Oncology | Hematology | Oncology
Advanced in Gliosarcoma
Dr. Selena J. Stuart
Hematology Oncology | Hematology | Oncology

Texas Oncology PA

1448 Common St, 
New Braunfels, TX 
 (32.3 miles away)
830-643-1762
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Selena Stuart is a Hematologist Oncology specialist and a Hematologist in New Braunfels, Texas. Dr. Stuart is rated as an Advanced provider by MediFind in the treatment of Gliosarcoma. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Glioma, and Oligodendroglioma. Dr. Stuart is currently accepting new patients.

Advanced in Gliosarcoma
Dr. Sreedevi Daggubati
Hematology Oncology | Hematology | Oncology
Advanced in Gliosarcoma
Dr. Sreedevi Daggubati
Hematology Oncology | Hematology | Oncology

Texas Oncology PA

1448 Common St, 
New Braunfels, TX 
 (32.3 miles away)
830-643-1762
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Sreedevi Daggubati is a Hematologist Oncology specialist and a Hematologist in New Braunfels, Texas. Dr. Daggubati is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. Her top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Paget Disease of the Breast, and Breast Cancer. Dr. Daggubati is currently accepting new patients.

Advanced in Gliosarcoma
Dr. Alexander S. Zweibach
Hematology Oncology
Advanced in Gliosarcoma
Dr. Alexander S. Zweibach
Hematology Oncology
1448 E Common St, 
New Braunfels, TX 
 (32.3 miles away)
830-643-1762
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Alexander Zweibach is a Hematologist Oncology provider in New Braunfels, Texas. Dr. Zweibach is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Melanoma, and Paget Disease of the Breast. Dr. Zweibach is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Arora's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 38 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile